Maternal RSV Vaccination and Infant Nirsevimab in Türkiye: Awareness, Uptake, and Prevention Preferences
Vaccines · 31.10.2026 · 14 (11) · 949
DOI: 10.3390/vaccines14110949 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vaccines, online erschienen am 31.10.2026. Verfasst von Atilla Guray und 2 weiteren Autor:innen. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Respiratory syncytial virus (RSV) is an important cause of respiratory disease and hospitalization in infants. Maternal RSV prefusion F (RSVpreF) vaccination and infant nirsevimab offer distinct preventive strategies. This study evaluated pregnant women’s awareness of RSV and these interventions, information sources, maternal vaccination receipt, and prevention preferences.
Methods
This cross-sectional study included 355 pregnant women recruited consecutively at a private hospital. Data were collected using a structured questionnaire. Access to vaccination services and the content of prior healthcare counseling were not directly assessed. Maternal vaccination receipt was assessed at ≥24 weeks of gestation. Modified Poisson regression with robust standard errors was used to evaluate factors associated with maternal vaccination receipt.
Results
RSV awareness was 70.1%, and 53.2% recognized RSV-related complications. Awareness of maternal RSVpreF vaccination and its perceived availability were 52.4% and 47.0%, respectively, among all participants. Among 222 women at ≥24 weeks of gestation, 60 (27.0%) had received maternal vaccination. Of the 130 vaccine-aware women in this gestational-age group, 60 (46.2%) had been vaccinated, indicating that awareness did not consistently translate into vaccination uptake. Insufficient information was the most frequently reported reason for nonvaccination. Awareness of nirsevimab and its perceived availability were 32.7% and 26.5%, respectively. Among 249 RSV-aware women, 48.6% selected neither intervention, 43.8% maternal vaccination, and 7.6% nirsevimab. Higher education (aPR, 2.10; 95% CI, 1.25–3.52), previous childbirth (aPR, 3.05; 95% CI, 1.94–4.81), and gestational age (aPR, 1.06; 95% CI, 1.01–1.11) were associated with vaccination receipt; unmeasured access and counseling factors may also influence uptake.
Conclusions
Limited awareness of RSV prevention strategies and the frequent selection of neither intervention highlight the importance of balanced, evidence-based antenatal counseling.
Zitieren
APA
Guray, A., Sasihuseyinoglu, A. S., & Guray, F. (2026). Maternal RSV Vaccination and Infant Nirsevimab in Türkiye: Awareness, Uptake, and Prevention Preferences. Vaccines, 14(11), 949. https://doi.org/10.3390/vaccines14110949
Vancouver
Guray A, Sasihuseyinoglu AS, Guray F. Maternal RSV Vaccination and Infant Nirsevimab in Türkiye: Awareness, Uptake, and Prevention Preferences. Vaccines. 2026;14(11):949. doi:10.3390/vaccines14110949
BibTeX
@article{Guray2026,
author = {Guray, Atilla and Sasihuseyinoglu, Ayse Senay and Guray, Fatma},
title = {Maternal RSV Vaccination and Infant Nirsevimab in Türkiye: Awareness, Uptake, and Prevention Preferences},
journal = {Vaccines},
year = {2026},
volume = {14},
number = {11},
pages = {949},
doi = {10.3390/vaccines14110949}
}
EUVIMED